Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib
Wang Qun*, Yin Tao, Duan Chuan Yi, Lu Weijun, Wang Yang and Fu Chang Bo
Department of Hepatopancreatobiliary Surgery ,Hu bei Cancer Hospital, PR China
- *Corresponding Author:
- Wang Qun
Department of General Surgery
Zhongnan Hospital of Wuhan University
Hubei Province, PR China
E-mail: [email protected]
Received date: January 09, 2016; Accepted date: May 02, 2016; Published date: May 06, 2016
Citation: Qun W, Tao Y, Yi DC, Weijun L,Yang W, et al. (2016) Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib. J Integr Oncol 5:164. doi:10.4172/2329-6771.1000164
Copyright: © 2016 Qun W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Hepatic carcinoma (HCC) has rised in China because of hepatitis B virus(HBV) effection, it has been famous for devastating malignancy as well as little treatment effect for HCC Sorafenib, has been successfully applied for solid tumors such as renal cancer, hepatocellular carcinoma. Sorafenib used alone or combination with others can induce growth-inhibition and apoptosis in vitro experiment. Sorafenib now was suggested to advanced hepatic carcinoma patient unqualitied for hepatectomy and transplant. Methods: A team of advanced hepatic carcinoma patients were enrolled for Sorafenib monotherapy or combination with HIAC,TACE, systemtic chemotherapy with arsenic trioxide and octreotide on base of personal disease progress CT and level of AFP were used to assess the tumor effect for decision of next treatment plan, An individualization treatment plan was performed ultimately. Result: Patients of initially HCC were extended survival time by Sorafenib monotherapy or combination with HIAC and TACE. TACE made hepatic lesion stable, added therapy of arsenic trioxide could be able to make TACErefractory and lung metatasis lesion under control. Conclusion: Sorafenib monotherapy or combination with others added therapy on needs of patients personal disease progress can extend survival time. Sorafenib applied individually may be more effective.